CoChat

A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI

Open access
Peters, Oliver, Lorenz, D., Fesche, A., Schmidtke, K., Hüll, M., Perneczky, R., Rüther, E., Möller, H.-J., Jessen, F., Maier, W., Kornhuber, J., Jahn, H., Luckhaus, C., Gertz, H.-J., Schröder, J., Pantel, J., Teipel, S., Wellek, S., Frölich, L., Heuser, I. · 2012 · The Journal of nutrition, health and aging
Cited by 55

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Mild cognitive impairment (MCI) is etiologically heterogeneous, and a substantial proportion of MCI subjects will develop different dementia disorders. One subtype of this syndrome, amnestic MCI, occurs preferentially but not exclusively in prodromal AD and is characterized by defined deficits of episodic memory. DESIGN, SETTING AND PARTICIPANTS: For a 2-year, double-blinded, placebo-controlled study MCI patients, presenting with an amnestic syndrome but not necessarily based on presumed prodromal AD were randomized. INTERVENTION: Patients received (a) a combination of 16 mg galantamine plus 20 mg memantine, or (b) 16 mg galantamine alone or (c) placebo. MEASUREMENTS: The primary objective was to explore the differential impact of these interventions on the progression to dementia and on cognitive changes as measured by the ADAScog. RESULTS: After recruitment of 232 subjects, the trial was halted before reaching the planned sample size, because safety concerns arose in other studies with galantamine in MCI. This resulted in a variable treatment duration of 2-52 weeks. The statistical analysis plan was amended for studying cognitive effects of discontinuing the study medication, which was done separately for galantamine and memantine, and under double-blind conditions. There was one death, no unexpected severe adverse events, and no differences of severe adverse events between the treatment arms. The cognitive changes on the ADAScog were not different among the groups. Only for the subgroup of amnestic MCI with presumed AD etiology, a significant improvement of ADAScog score over placebo before the discontinuation of medication was observed, while amnestic MCI presumably due to other etiologies showed no cognitive changes with broad variation. Cognitive improvement was numerically larger in the combination treatment group than under galantamine alone. Patients who received placebo declined as expected. Discontinuation of galantamine, either as part of the combination regimen or as mono treatment, resulted in a transient decline of the ADAScog score in amnestic MCI of presumed AD etiology, while discontinuation of Memantine did not change the cognitive status. CONCLUSION: In an interrupted trial with amnestic MCI subjects the combination of galantamine plus memantine were generally well tolerated. In the subgroup of MCI subjects with presumed AD etiology, a cognitive benefit of a short-term combination treatment of galantamine plus memantine was observed, and cognitive decline occurred after discontinuation of galantamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12603-012-0062-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 55

Metadata

Authors
Peters, O., Lorenz, D., Fesche, A., Schmidtke, K., Hüll, M., Perneczky, R., Rüther, E., Möller, H.-J., Jessen, F., Maier, W., Kornhuber, J., Jahn, H., Luckhaus, C., Gertz, H.-J., Schröder, J., Pantel, J., Teipel, S., Wellek, S., Frölich, L., & Heuser, I.
Venue
The Journal of nutrition, health and aging
Publisher
Elsevier BV
Published
2012-06
Volume
16
Issue
6
Pages
544-548
ISSN
1279-7707 (ISSN-L)
OpenAlex
W2065168181
Cited by
55
References
2
FWCI
3.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. https://app.cochat.ai/papers/10.1007/s12603-012-0062-8
The paper
Peters, O., Lorenz, D., Fesche, A., Schmidtke, K., Hüll, M., Perneczky, R., Rüther, E., Möller, H.-J., Jessen, F., Maier, W., Kornhuber, J., Jahn, H., Luckhaus, C., Gertz, H.-J., Schröder, J., Pantel, J., Teipel, S., Wellek, S., Frölich, L., & Heuser, I. (2012). A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. The Journal of nutrition, health and aging. https://doi.org/10.1007/s12603-012-0062-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.